The inhibitory effect of cranberry juice on phenytoin metabolism by human liver microsomes

Japanese Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 2, 2009, Pages 59-64

  Ushijima, Kentarou ^a   Koshimizu, Taka Aki ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cranberry juice; CYP2C9; Human liver microsomes; Interaction, phenytoin

Indexed keywords

CRANBERRY EXTRACT; CYTOCHROME P450 2C9; FLUVOXAMINE; PHENYTOIN;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; CRANBERRY JUICE; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; IC 50; LIVER MICROSOME;

EID: 67049155898     PISSN: 03881601     EISSN: None     Source Type: Journal    
DOI: 10.3999/jscpt.40.59     Document Type: Article

References (16)

1. Miners JO, Birkett DJ. Cytochrome P4502C9 : an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998 : 45 : 525-38.
2. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9 : drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005 ; 45 : 477-94.
3. Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ 2003 : 327 : 1454.
4. Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. Am J Ther 2006 : 13 : 283-4.
5. Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine. and midazolam-probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther 2007 : 81 : 833-9.
6. Ansell J. McDonough M, Harmatz JS, Greenblatt DJ. A randomized, double-blind trial of the interaction between cranberry juice and warfarin./ Thromb Thrombolysis 2008 : 25 (1) : 112.
7. Greenblatt DJ, von Moltke LL. Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole : in vitro and clinical studies. Clin Pharmacol Ther 2006 : 79 : 125-33.
8. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996 ; 24 : 1401-3.
9. Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, et al. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos 2004 : 32 : 828-33.
10. Koshimizu TA, Ueno S, Tanoue A, Yanagihara N, Stojilkovic SS, Tsujimoto G. Heteromultimerization modulates P2X receptor functions through participating extracellular and C-terminal subdomains./Bio/ Chem 2002 : 277 : 46891-9.
11. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995 ; 25 : 261-70.
12. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001 ; 29 : 23-9.
13. Lin T, Pan K, Mordenti J, Pan L. In vitro assessment of cytochrome P450 inhibition : strategies for increasing LC/MS- based assay throughput using a one-point IC (50) method and multiplexing high-performance liquid chromatography. J Pharm Sci 2007 ; 96(9) : 2485-93.
14. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes : effects of contents of these two forms in individual human samples. / Pharmacol Exp Ther 1997 : 283 : 434-42.
15. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6by fiuvoxamine.BrJ Clin Pharmacol 19% : 42 : 518-21.
16. Yukawa E. Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring. Clin Pharmacokinet 19% ; 31 : 120-30.